Metabasis is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs by applying its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways. The Company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' product pipeline represents drug candidates indicated for the treatment of metabolic diseases such as hyperlipidemia and diabetes, among others. Additionally, our pipeline includes drug candidates for the treatment of liver diseases such as hepatitis and primary liver cancer which the company plans to license. All product candidates were developed internally using proprietary technologies including the Company's NuMimetic and HepDirect technologies.




May 14, 2009

Metabasis Therapeutics, Inc. (Nasdaq: MBRX), a biopharmaceutical company focused on innovative therapies for metabolic diseases including hyperlipidemia and diabetes, today announced financial results for the first quarter ended March 31, 2009.more

May 8, 2009

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) a biopharmaceutical company focused on innovative therapies for metabolic diseases including hyperlipidemia and diabetes, today announced that it will hold a conference call to discuss the Company’s first quarter financial results.more

 

 



 


Building on a Solid Base

©2008 Copyright, Metabasis Therapeutics, Inc. San Diego, CA